KR910011818A - Aids 치료에 유용한 hiv 프로테아제 억제제 - Google Patents
Aids 치료에 유용한 hiv 프로테아제 억제제 Download PDFInfo
- Publication number
- KR910011818A KR910011818A KR1019900021105A KR900021105A KR910011818A KR 910011818 A KR910011818 A KR 910011818A KR 1019900021105 A KR1019900021105 A KR 1019900021105A KR 900021105 A KR900021105 A KR 900021105A KR 910011818 A KR910011818 A KR 910011818A
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxy
- phenyl
- ethoxy
- methyl
- morpholinyl
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title claims 5
- 239000004030 hiv protease inhibitor Substances 0.000 title 1
- -1 direct Chemical group 0.000 claims 169
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims 68
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 19
- ZRLFRWNYFMYZEG-UHFFFAOYSA-N 2-methylhexanamide Chemical compound CCCCC(C)C(N)=O ZRLFRWNYFMYZEG-UHFFFAOYSA-N 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 5
- WPZDTIQWEZHXJB-MRXNPFEDSA-N CCCC[C@@H](C)C(=O)NC1=CC=C(C=C1)OCCN2CCOCC2 Chemical compound CCCC[C@@H](C)C(=O)NC1=CC=C(C=C1)OCCN2CCOCC2 WPZDTIQWEZHXJB-MRXNPFEDSA-N 0.000 claims 5
- 150000001412 amines Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 claims 4
- 108010010369 HIV Protease Proteins 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 2
- GUESAUYJUSDRGO-QGZVFWFLSA-N CCCC[C@@H](C)C(NC(C=C1)=CC=C1OCCN1CCN(C)CC1)=O Chemical compound CCCC[C@@H](C)C(NC(C=C1)=CC=C1OCCN1CCN(C)CC1)=O GUESAUYJUSDRGO-QGZVFWFLSA-N 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- QNRXNRGSOJZINA-QMMMGPOBSA-N (2s)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-QMMMGPOBSA-N 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-O 1-azoniabicyclo[2.2.2]octane Chemical compound C1CC2CC[NH+]1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-O 0.000 claims 1
- RMOHQZGAPOHERV-UHFFFAOYSA-N 2-(2h-thiochromen-2-ylsulfonyl)-2h-thiochromene Chemical compound S1C2=CC=CC=C2C=CC1S(=O)(=O)C1C=CC2=CC=CC=C2S1 RMOHQZGAPOHERV-UHFFFAOYSA-N 0.000 claims 1
- JSWKBJIKVSXWDJ-UHFFFAOYSA-N 2-(oxolan-3-yl)acetic acid Chemical compound OC(=O)CC1CCOC1 JSWKBJIKVSXWDJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 claims 1
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 claims 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- TWSIYGATPWEKBK-UHFFFAOYSA-N 4h-1,3-benzodioxine Chemical compound C1=CC=C2OCOCC2=C1 TWSIYGATPWEKBK-UHFFFAOYSA-N 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 125000006177 alkyl benzyl group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 1
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000004673 propylcarbonyl group Chemical group 0.000 claims 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (24)
- 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.A-G-B-B-J (Ⅰ)상기식에서, A는 1)수소; 2)〔여기에서, R1은 수소이거나, a) ⅰ)C1-4알킬; ⅱ)하이드록시; ⅲ)카복시; ⅳ)할로〔여기서, 할로는 F, Cl, Br 또는 I이다); ⅴ)아미노; ⅵ)C1-3알콕시카보닐; ⅶ)테트라하이드로피란에 의해 치환되거나 비치환된 C1-3알콕시; ⅷ)-CONR2R3(여기서 R2및 R3은 동일하거나 상이하며, 수소, C1-5알킬 또는 C1-5알콕시 알킬이거나; R2및 R3이 함께 직접, 피롤리디날 또는 피페리딜과 같은 5원 내지 7원 헤테로사이클을 형성하거나; R2와 R3이 N, O 및 S 중에서 선택된 헤테로원자를 통해서는 R2와 R3이 결합되어 있는 질소원자와 함께 모르폴리닐, 피페라지닐 또는 N-C1-3알킬피페라지닐과 같은 6원 헤테로사이클을 형성한다); ⅸ)NR2R3;ⅹ)(여기서 R은 수소이거나 C1-4알킬이고;D는이며;R4는 N, C1-3알킬, C1-4알콕시 또는 NR2R3이다); xi)C3-7사이클로알킬; 또는 C6-10아릴 xii)푸릴 또는 모르폴리노와 같은 포화되거나 불포화된 5원 또는 6원 헤테로사이클이거나; 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로사이클릭 환(여기서, 환(들)은 ⅰ)옥소, ⅱ)-OH, ⅲ)NH 또는 ⅳ)C1-4알킬에 의해 치환되거나 비치환된다); ⅷ) (a) 할로, (b) 하이드록시, (c) C1-3알콕시, (d) C1-3알킬, (e) NR2(여기서, R은 상기에서 정의한 바와 같다). (f), (g), (h) -CH2NR2, (j)또는 (k)중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C6-10아릴 또는 C6-10카보사이클릭; 및 xiv) -O-〔CH2)mO〕n-R (여기서, m은 2 내지 5이고, n은 0 내지 5이다) 중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C1-6알킬 또는 C1-6알케닐; b) ⅰ)C1-4알킬, ⅱ)C1-3알콕시, ⅲ)하이드록시, ⅳ)할로, ⅴ)-NR2, ⅵ), ⅶ), ⅷ) -SO2NR2, ⅸ) -CH2NR2, ⅹ) -NRCOR 또는 xi) -NRSO2R중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C6-10아릴; 또는 c) 5원 또는 6원 헤테로사이클이다〕; 3) R1-SO2-; 4)(여기서, R5는 H 또는 C1-5알킬이거나, R5는 R1과 함께 직접, 피롤리디닐 또는 피페리디닐과 같은 5원 내지 7원 헤테로사이클을 형성하거나 R1과 R5가 N, O 및 S중에서 선택된 헤테로원자를 통해서 R1과 R5가 결합되어 있는 질소원자와 함께 모르폴리닐, 피페리지닐 또는 N-C1-3알킬- 피페라지닐과 같은 6원 헤테로사이클을 형성한다); 5)〔여기서, R6, R7및 R6은 독립적으로 a) H; b) ⅰ) 할로, ⅱ) OH, ⅲ) 아릴 SO2- 및 ⅳ) -O-〔CH2)mO〕n-R 중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 C1-6알킬, ⅰ)C1-4알킬, ⅱ) C1-3알콕시, ⅲ) 할로, ⅳ) 니트로, ⅴ) 아세톡시, ⅵ) 디메틸아미노카보닐, ⅶ) 페닐 및 ⅷ) C1-3알콕시카보닐중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 아릴; d) 플루오르에닐; e) R6, R7및 R8은 독립적으로 결합되어 C3-10사이클로알킬(예:아다만틸), 사이클로펜틸 또는 사이클로헥실인 모노사이클릭, 비사이클릭 또는 트리사이클릭 환계를 형성할 수 있으며, 또한 C1-4알킬에 의해 치환될 수 있거나; f) 피리딜, 푸릴, 1,3-디옥슬란 또는 테트라 하이드로푸릴과 같은 포화되거나 불포화된 5원 내지 7원 헤테로사이클릭 환이거나; 벤즈이속사졸릴 또는 4H-1,3-벤조디옥신과 같은 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로사이클릭 환((들)은 C1-4알킬에 의해 치환되거나 비치환된다)이거나; g) R6, R7및 R8은 독립적으로 결합되어 5원 내지 7원 헤테로사이클릭 환을 형성할 수 있거나; ⅰ) 아세틸옥시, ⅱ) C1-4알킬, ⅲ) 하이드록시, ⅳ) 하이드록시 C1-4알킬, ⅴ) 알킬옥시알킬, ⅵ) 페닐 알콕시 및 ⅶ) 알콕시중에서 선택된 1개 이상의 치환체에 의해 치환되거나 비치환된 포화되거나 불포화된 7원 내지 10원 비사이클릭 헤테로 사이클릭 환을 형성할 수 있다〕; 또는8)〔여기에서, Z는 O,S 또는 HH이고; R4및 R10은 독립적으로 a) -(CH2)n-R11또는 b) C1-4알케닐 -R4(여기서 n은 0 내지 5이다)이고; R9및 R10은 각각 또는 둘다 R12에 의해 치환되어야 하며; R11은 a) 수소; b) C1-4알킬; c) 하이드록시로 임의로 치환된 C5-C10사이클로알킬, d) R12로 치환되거나 비치환되고, 하나 이상의 ⅰ) 할로, ⅱ) C1-4알킬, ⅲ) C1-3알콕시 또는 ⅳ) 하이드록시로 임의로 치환된 C6-C10아릴; 또는e)N,O,S중에서 선택된 1 내지 3개의 헤테로원자를 함유하는 모노사이클릭 또는 비사이클릭 헤테로사이클 〔여기서, 헤테로사이클은 비치환되거나 R12및 임의로 하나 이상의 i) 할로, ⅱ)C1-4알킬 또는 ⅲ)C1-3알콕시로 치환된 것이다)이고; R12는 a)-X-(CH2)m-NR13R14〔여기서, X는 -O-, -S- 또는 -NH-이고 m은 2 내지 5이며, R13및 R14는 독립적으로 수소이거나 i)C1-6알킬, ⅱ)하나 이상의 (a)C1-3알콕시, (b)-OH 또는 (c)-NR2(여기서, R은 수소 C1-4알킬이다)로 치환된 C1-6알킬, ⅲ)동일하거나 상이하며 함께 결합되어 -NR, -O-,-S-,또는 -SO2- 중에서 선택된 추가 헤테로원자수 2의 모르폴리노와 같은 5 내지 7원 헤테로사이클을 형성하고 (여기서, 헤테로사이클은 임의로 C1-4알킬로 치환된 것이다); iv)비치환디거나 하나이상의 (a) C1-4알킬 또는 (b)-NR2로 치환되거나 비치환된 방향족 헤테로사이클이다〕; b)-(CH2)q-NR13R14〔여기서, q는 1 내지 5이고,R13및 R14는 상기에서 정의한 바와 같으나, R13또는 R14는 H 또는 C1-6알킬이 아니다〕; 또는 c) 벤조푸릴, 인돌릴, 아자사이클로알킬, 이지비사이클로 C7-11사이클로알킬, 또는 비치환되거나 C1-4알킬로 치환된 벤조 피페리디닐미며, R15는 -OH 또는 - NHR16〔여기서 , R16은 -H, -,- C1-4알킬 또는 -COOR 이다〕이고;는 1) 하나 이상의 (a) C1-4알킬; b) 하이드록시; c) -NR2; d) -COOR; e)- CONGR;f) -NHSO2R; g); h) 아릴; i) C1-4알킬로 치환된 아릴; j) 헤테로사이클; 또는 k) C1-4알킬로 치환된 헤테로사이클로 치환되거나 비치환된 C3-17사이클로알킬이고,[여기서, R16은 상기에서 저의한 바와 같고, X는 O.S 또는 NH 이며, W는 1) OH, 2) NH23) OR, 또는 4) NHR 이다〕이며, B는 존재하지 않거나 독립적으로 -[여기서, R21은 a)-CH(CH3)2, b)-CH(CH3) (CH2CH3) 또는 c)-페닐이다〕이고, J는 1) YR17[여기서, Y는 O 또는 NH 이고, R17은 a)H; b) -C1-6알킬, 하나이상의 ⅰ)-NR2, ⅱ) -OR, ⅲ) -NHSO2C1-4알킬, ⅳ) -NHSO2아릴, 또는 -NHSO2(디알킬-아미노아릴), v) -CH2OR, vi) -C1-4알킬, vii)viii)ix)또는x)xi)xii)xiii) -NR3A(여기서, A는 반대이온이다), xiv) -NR18R18(여기서, R18및 R19는 동일하거나 상이하며 C1-5알킬과 함께 결합하여 -O-, -S-, 또는 -NR-중에서 선택된 하나이하의 추가의 헤테로원자를 함유하는 5 내지 7원 헤테로사이클을 형성한다), xv) 아릴, xvi) -CHO, xvii, -OR(O)(ORx)2(여기서 Rx는 H 또는 아릴이다), 또는 xviii) 하나이상의 아민 또는 4급 아민 또는 -O-[(CH2)mO]n-R 로 치환된알킬; 또는 -OP(O)(ORx)2로 치환되거나 비치환된 -C1-6알킬; 또는 c)-O-[(CH2)mO]nO]nH이다], 2)N(R17)2, 또는 3) -NR18R19[여기서, R15및 R19는 상기에서 정의한 바와 같다], 또는 4)[여기서, Y, R17및 n은 상기에서 정의한 바와 같고, R20은 a) 수소; b)하나이상의) i)할로, ii)-OR (여기서, R은 H 또는 C1-4알킬이다), iii)iv)v) -CH2NR2, vi) -SO2NR2, vii) -NR2, viii)xi) C1-4알킬, x) 페닐, xi) -CF3, xii)xiii) -C1-4알킬 -NR2xiv) -OP(O)(ORx)2(여기서, Rx는 H또는 아릴이다). 또는 xv) 하나이상의 아민 또는 4급 아민으로 치환된알킬 또는 -OP(O)(ORx)2로 치환되거나 비치환된 아릴; c)치환되거나 비치환된 5 내지 7원 헤테로사이클릭환 또는 7 내지 10원 비사이클릭 헤테로사이클릭환, 예를들면, 이소크로만, 크로만, 이소티오크로만, 티오크로만, 벤즈이미다졸, 벤조티오피란, 옥소벤조 티오피란, 벤조피란, 벤조티오파라닐설폰, 벤조티오파라닐설폭사이드(여기서, 환 또는 환들은 하나 이상의 i) 할로, ii)-OR(여기서, R은 H, C1-4알킬 또는 C1-4알케닐이다)(여기서, Rx는 H 또는 아릴이다), xv) 하나이상의 아민 또는 4급 아민 또는 -OP(O)(ORx)2치환된치환되거나 비치환된다); d)포화되거나 불포화된 5 내지 7원 카보사이클릭 또는 7 내지 10원 비사이클릭 카보사이클릭 환, 예를들면 사이클로펜탄, 사이클로헥산, 인단, 노르보란 또는 나프탈렌(여기서, 카보사이클릭 환은 하나이상의 i) 할로 ii)-OR 또는 -CH2OR(여기서, R은 H 또는 C1-4알킬이다),(여기서, R21은 H, -(CH2)n-NR2, C1-16알킬, 피리딘, -(CH2)nNR-(CH2)n-NR2, -(CH2)n,-[(CH2)mO]n-R,R로 치환된 퀴뉴클리디니우밀, 1회 이상 R로 치환된 피페라진 -C1-4알킬-벤질 또는 모르폴리노알킬벤질이다), iv), v)-CH2NR2, vi) -SO2NR2, vii) -NR2, viii)xi) C1-6알킬, x)페닐, xi) -CF3,xiii) -OP(O)(ORx)2(여기서, Rx는 H 또는 아릴이다) xiv) 하나이상의 아민 또는 4급 아민으로 치환된알킬, -OP(O)(ORx)2, 또는 -O-[(CH2)mO]n-R 또는로 치환되거니 비치호나 된다)이다]이다.
- 제1항에 있어서,인 화합물.
- 제2항에 있어서, B가 존재하지 않거나 존재하고 Q가인 화합물.
- 제3항에 있어서, B가 존재하지 않고 J가 NH-R16(여기서, R20은 7원 내지 10원 포화 또는 불포화 비사이클릭 카보사이클릭 또는 헤테로사이클릭환이다)인 화합물.
- N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-((2-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(2-하이드록시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(에록시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥산아미드, N-(2-벤즈아미돌릴메틸)-N-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥사노일 이소로이실 아미드, N-(2-벤즈아미돌릴메틸)-N-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)헥사노일 이소로이실 아미드, N-))피롤로[3,2-b]피리딘-2-일)메틸)-N'-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐-헥사노일 이소로이실 아미드, N-((5-(2-모폴리닐에틸)피롤로[3,2-b]피리딘-2-일)메틸)-N'-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)-2(R)-(3'-페닐프로프-2-',엔-1-일)-헥사노일 이소로이실 아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-페닐메틸핵산아미드, N-(2(S, 3-(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-벤조피라닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-벤조피라닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리노)에톡시)페닐-2(R)-(4-하이드록시페닐)-메틸)핵산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)핵산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-(4-(2-(4-모폴리닐)에톡시)페닐)2-(R)-((3-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),3-(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-모폴리닐)프로필옥시)페닐)메틸)헥산아미드, N-(2(S)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((3-(2-(4-피롤리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(S),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-디메틸아미노에톡시)페닐)메틸)헥산아미드, N-(2(S),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-피페리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-피롤리디닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸(아미노)에톡시)페닐)-메틸)헥산아미드, N-(2(R),-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-티아모폴린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-(1-옥소티아모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-(1,1-옥소티아모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(1-(4-메틸피페라진-1-일)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디메틸아미노아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(S), 3(R)-디아세톡시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(3-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-디하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(5-(2-(4-모폴리닐)에톡시)-2-벤즈아미다졸릴-메틸))-5(S)-1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)벤즈이미다졸릴메틸)5(S)-(1,1-디에틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2-메틸프로필아미노)에톡시)페닐)메틸)헥산아미드, N-(3(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-((3-피리딘키보닐옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-n-헥사데카노일옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(3,5-디메틸모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2,6-디메틸모풀린-4-일)에톡시)페닐)메틸)헥산아미드, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(2,2,6,6-테트라메틸피페리딘-4-일)-아미노-에톡시)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(3-(4-모폴리닐)프로필)페닐)메틸)헥산아미드, N-2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(4-모폴리닐)메닐페닐)메틸 헥산아미드, n-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(3-(비스(2-메톡시에틸)아미노)프로필)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐(-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)하이드록시-6-페닐-2(R)-((4-(3-(1-티아모풀린-4-일)프로필)페닐-메틸)헥산아미드, N-(2(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-이미다졸릴)에톡시)페닐)메틸)헥산아미드, N-(3(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(1-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-아미노-2(R)-하이드록시-1(S)-인다닐)-5(S)-1(1,2-디메틸-2-하이드록시에틸)포스토로아미데이토-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드,하이드록시-6-페닐-2(R)-((4-92-(4-모폴리닐)에톡시)페닐)메틸)헥산이미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-비사이클로[2,2,1]헵틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((3-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸-1-(2-테트라하이드로푸라닐)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸-1-(3-테트라하이드로푸라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-테트라하이드로피라닐)메톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시아세틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-메톡시에톡시)아세틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-(2-메톡시에톡시)아세탈아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(R)-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(S)-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3-테트라하이드로푸라닐)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메틸프로필옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-(2-(2-메톡시에톡시)에톡시)에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에록시카보닐-N-메틸아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디ㅣㅣ메틸에톡시에톡시)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((카보벤질옥시)아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-피리딜메틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-프로필옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-부틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(n-펜틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-3(S),4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(4(R)-하이드록시-2(R)-메틸-1(R)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-5(S-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),3(R)-디하이드록시-5(R)-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R),3(R)-디하이드록시-5(S)-메틸-1(S)-사이클로펜틸)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-3(S)-디하이드록시-4(S)-티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-1(S)-옥소-4(R)-티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-사이클로[4,3,0]노닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(1(R,S)-옥소-4(S)-이소티오크로마닐-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(1,1-디메틸에톡시카보닐)아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-아자비사이클로[2,2,2.]옥타닐-1-아미뉴밀)에톡시)-페닐메틸헥산아미드, N-[(1-하이드록시사이클로헥실)메틸]-5(S)-t-부톡시카보닐아미노-4(S)-하이드록시-6-페닐02(R)-(4-[2-모폴리노에톡시]-페닐)메틸헥산아미드, N-(3(S)-아미노-2(R)-하이드록시-1(S)-인다닐)-(S)-t-부톡시카보닐아미노-(4S)-하이드록시-6-페닐-2(R)-(4-[2-모폴리노에톡시]-페닐)메틸헥산아미드, N-(2(R)-하이드록시-3A,4,,5,6,7,7A, 헥사하이드로-인단-1(S)-일)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-2(R)-((3-카복시프로파노일)옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-석시노일아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노)에톡시)페닐메틸]헥사아미드, N-(2(R)-[(2-(2-(2-메톡시에톡시)에톡시)에톡시)-카보닐]옥시)-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시-카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4-테트라하이드로피라닐)아세트아미도)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-[(시스-2(R)-(1'-메틸-3'(S)-퀴누클리디뉴밀카보닐)옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-아세틸아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-[(시스-2(R)-[4-(4-메틸-1-피페라지닐메틸)벤조일]옥시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[2(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-부티닐아미노]-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(5-옥소-2(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-[(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[2(S)(아미노-4-하이드록시부틸릴)아미노]-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐-5(S)-[1-트란스-(2-하이드록시인다닐리데닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)0[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1-시스-(2-하이드록시인다닐데닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]-헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-하이드록시-1인다닐메틸)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(4-모폴리닐)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(3,6,9,12-테트라옥사트리데실카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-(헥사하이드로푸로[2,3-b]푸라닐-3A-옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시01(S)-인다닐)-5(S)-[(2,2-디메틸-1,3-디옥슬란-메틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에폭시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-푸라닐메톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리노)에톡시)페닐)메틸-6-사이클로헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((3-(R,S)-테트라하이도로푸라닐)아세트아미드)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리노)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((2(R,S)-테트라하이드로푸라닐)아세트아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-((4,5-디하이드로-3(2H)-푸릴리덴)하세트아미도)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-케닐피페라지닐)에톡시)페닐)메틸헥산-아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메틸옥시카보닐]아미노)-4(S)-하이드록시-6-페닐-2(R)-(3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-메톡시에톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디에틸아미노)에톡시)페닐)메틸-헥산아미드, N-2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1,-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디이소프로필아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-히이드록시-6-(4-(2-디메틸아미노에톡시)페닐)-2(R)-(3-페닐-2-프로펜-1-일)-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R,S-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시)-1(S)-인다닐)-5(S)-(5-(2-아세톡시-1,4:3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록ㄷ시-1(S)-인다닐)-5(S)-(3(S)-메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틱헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(R)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틱헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(2-아세톡시-1,4:3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐) -5(S)-3(S) -메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-92(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4-(S)-하이드록시-6-페닐-2(R)-4(2-(2-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메톡시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노(-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(6(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노(-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(R)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-5(S)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(2-메톡시에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(S)-하이드록시-1(S)-벤조피라닐-5(S)-(3,6,9,12-테트라옥사트리데실카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(헥사하이드로푸로[2,3-b]푸라닐-3A-옥사카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-모폴리닐]에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인디닐)-5(S)-[(2,2-디메틸-1,3-디옥슬란-메틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(N'-아세틸네우르아미노일]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐]메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(1,3-비스(메톡시에톡시))프로폭시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-모폴리노에톡시)페닐]메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-[5(R)-하이드록시메틸-3(S)-메톡시테트라하이드로푸라닐옥시아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-(4-모폴리노에톡시)페닐)메틸]헥산아미드, 2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-메틸-3-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모플리닐)에톡시)페닐)메틱헥산아미드, N-(시스-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(3-메톡시-1-부틸옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-(4-모풀리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(1-메톡시-2-프로필옥시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-(1,3-비스(메톡시)프로폭시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-(4-모폴리노)에톡시)페닐)메틸헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-(1,4-벤조디옥사닐)메틸)옥시카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2,2-디옥스-4(S)-이소티오크로마닐)-5(S)-[1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R, S )-옥소-4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2,3-비스-메톡시에틸옥시)프로필카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[4H-테ㅡ라히드로-4-피라닐옥시메틸카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-[4-(2-(4-모폴리노)에톡시)(페닐메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐-L-아스파리기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-[4-(2-(4-모폴리노)에톡시)페닐메틸]헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[1,1-디메틸에톡시카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(4(S)-이소티오크로마닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-1(S)-안다닐)-5(S)-[[N-2-퀴놀릴카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[[4-(2-모폴리노에톡시)페닐)메틸)헥산아미드, N-(시스-2(R)-하이드록시-1(S)-인다닐)-5(S)-[[N-2-퀴놀릴카보닐-L-아스파라기닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[(4-(2-모폴리노에톡시)페닐)메틸]헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-네트라하이드로푸라닐)아세트아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-케닐피페라지닐)에톡시)페닐)메틸헥산-아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-[(2-푸라닐메틸옥시카보닐]아미노)-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-[(2-메톡시에톡시)카보닐]아미노-4(S)-하이드록시-6-페닐-2(R)-[3-(4-(2-모폴리노에톡시)페닐프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(3-(4-(2-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐)아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디에틸아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(디이소프로필아미노)에톡시)페닐)메틸-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보니아미노)-4(S)-하이드록시-6-(4-(2-디메틸아미노에톡시)페닐)-2(R)-(3-페닐-2-프로펜-1-일)-헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(R,S-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5-(1-아세톡시-1,4 : 3,6-디안하이드로-D-글루시틸)카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-4(S)-하이드록시-5(S)-(하이드록시메틸)-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-벤질옥시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(5(S)-메톡시메틸-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-5(S)-메톡시메틸-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-메톡시-5(S)-메톡시메틸-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1-(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보니랑미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(R)-인다닐)-5(S)-(3(S)-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(S)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-디에틸아미노에톡시)페닐)메틸)헥산아미드, N-(2-2(R)-하이드록시-1(S)-인다닐)-5(S)-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-N,N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4( S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-N,N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로포라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-)(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트란스-3-(4-(2-(4-모폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-1,1-디옥소테트라하이드로티오피라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(S)-하이드록시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-하이드록시-3(R)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(4(R)-메틸-3(S)-태트라하이드로푸라닝록시카비놀아미노)-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에톡시-카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-5-페닐-2(R)-(4-(2-(4-모폴리닐)에톡시)페닐)메틸헥산아미드인 화합물 또는 이의 약저학적으로 허용되는 염.
- N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노-4(S)-하이드록시-6-페닐-2(R)-(4-(2-(4-모프폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐-5(S)-에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모르폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-모르폴리닐)에톡시)페닐)메틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-1,1-디메틸에톡시카보닐아미노)-4-(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피레라지닐)에톡시)페닐)멘틸헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸)헥산아미드,N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1.1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(4-(2-(N.N-디-2-프로필)아미노에톡시)페닐)메틸헥산아미드, N-(2R)-하이드록시-1(S)-인다닐)-(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하일드록시-6-사이클로헥실-2(R)-(4-(2-(4-메틸-1-피페라지닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3(S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-사이클로헥실-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인디닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(3S)-테트라하이드로푸라닐옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드 또는 N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(2-메톡시에틸옥시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-(트랜스-3-(4-(2-(4-모르폴리닐)에톡시)페닐)프로프-2-엔-1-일)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- N-(2R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모프롤리닐)에톡시)페닐)메닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1-메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(N,N-비스(2-메톡시에틸)아미노)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, N-(2(R)-하이드록시-1(S)-인다닐)-5(S)-(1,1-디메틸에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, N-(2-(R)-하이드록시-1(S)-인다닐)-5(S)-(에톡시카보닐아미노)-4(S)-하이드록시-6-페닐-2(R)-((4-(2-(4-모프르폴리닐)에톡시)페닐)메틸)헥산아미드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 표의 항비루스제, 면역조절제, 항생제 또는 백신과의 배합물로의 제1항 내지 11항 중 어느 한 항의 화합물.
- 제1항 내지 11항중 어느 한 항의 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- 제12항에 따른 배합물의 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
- 제13항에 있어서, AIDS의 치료, HIV에 의한 감염의 예방, HIV에 의한 감염의 치료 또는 HIV 프로타아제의 억제에 있어 사용하기 위한 약제학적 조성물.
- 제14항에 있어서, AIDS의 치료, HIV에 의한 감염의 예방, HIV에 의한 감염의 치료 또는 HIV 프로타아제의 억제에 있어 사용하기 위한 약제학적 조성물.
- 유효량의 제1항 내지 11항중 어느 한 항의 화합물을 투여함을 특징으로 하여 AIDS를 치료하는 방법.
- 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 AIDS를 치료하는 방법.
- 유효량의 제1항 내지 11항중 어느 한 항의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 예방하는 방법.
- 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 예방하는 방법.
- 유효량의 제1항 내지 11항 중 어느 한 항의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 치료하는 방법.
- 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV에 의한 감염을 치료하는 방법.
- 유효량의 제1항 내지 11항중 어느 한 항의화합물을 투여함을 특징으로 하여 HIV 프로테아제를 억제하는 방법.
- 유효량의 제12항에 따른 배합물로의 화합물을 투여함을 특징으로 하여 HIV 프로테아제를 억제하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45291289A | 1989-12-18 | 1989-12-18 | |
US452912 | 1989-12-18 | ||
US59728690A | 1990-10-15 | 1990-10-15 | |
US597286 | 1990-10-15 | ||
US61965490A | 1990-12-04 | 1990-12-04 | |
US619654 | 1990-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR910011818A true KR910011818A (ko) | 1991-08-07 |
Family
ID=27412551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900021105A KR910011818A (ko) | 1989-12-18 | 1990-12-18 | Aids 치료에 유용한 hiv 프로테아제 억제제 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0434365A3 (ko) |
JP (1) | JPH05345775A (ko) |
KR (1) | KR910011818A (ko) |
CN (1) | CN1053607A (ko) |
AU (1) | AU6822990A (ko) |
CA (1) | CA2032259A1 (ko) |
FI (1) | FI906212A (ko) |
HU (1) | HU908295D0 (ko) |
IE (1) | IE904555A1 (ko) |
IL (1) | IL96691A0 (ko) |
NO (1) | NO905428L (ko) |
PT (1) | PT96234A (ko) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
US6878728B1 (en) | 1999-06-11 | 2005-04-12 | Vertex Pharmaceutical Incorporated | Inhibitors of aspartyl protease |
CA2093429A1 (en) * | 1990-10-09 | 1992-04-10 | Shieh-Shung T. Chen | Process for biophosphorylating organic compounds |
CN1071930A (zh) * | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂 |
US5508407A (en) * | 1991-07-10 | 1996-04-16 | Eli Lilly And Company | Retroviral protease inhibitors |
EP0528762B1 (de) * | 1991-08-15 | 1997-05-07 | Novartis AG | N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten |
CA2076204A1 (en) * | 1991-08-16 | 1993-02-17 | Samuel L. Graham | Hiv protease inhibitors with n-terminal polyether substituents |
EP0534511A1 (en) * | 1991-08-16 | 1993-03-31 | Merck & Co. Inc. | HIV protease inhibitors useful for the treatment of aids |
US5643878A (en) * | 1991-09-12 | 1997-07-01 | Ciba-Geigy Corporation | 5-amino-4-hydroxyhexanoic acid derivatives |
US5491149A (en) * | 1991-09-16 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Dihydroxypropylamine containing retroviral protease inhibitors |
KR100268694B1 (ko) | 1991-10-11 | 2000-10-16 | 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 | 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체 |
WO1993008184A1 (en) * | 1991-10-23 | 1993-04-29 | Merck & Co., Inc. | Hiv protease inhibitors |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
CA2195027C (en) * | 1991-11-08 | 2000-01-11 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
WO1993012138A1 (en) * | 1991-12-12 | 1993-06-24 | Schering Corporation | Compounds and compositions for treating hiv infections |
EP0550924A1 (en) * | 1991-12-16 | 1993-07-14 | Merck & Co. Inc. | 2-Pyrrolidinone derivatives as HIV protease inhibitors |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
RU2126794C1 (ru) * | 1992-03-11 | 1999-02-27 | Нархекс Лимитед | Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы |
US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
ATE253050T1 (de) | 1992-03-11 | 2003-11-15 | Narhex Ltd | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
DE4215874A1 (de) * | 1992-05-14 | 1993-11-18 | Bayer Ag | Dithiolanylglycinhaltige HIV-Proteaseinhibitoren vom Hydroxyethylenisostertyp |
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
IL106507A (en) * | 1992-08-07 | 1997-11-20 | Merck & Co Inc | Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type |
JP3657002B2 (ja) | 1992-08-25 | 2005-06-08 | ジー.ディー.サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
GB2270914A (en) * | 1992-09-14 | 1994-03-30 | Merck & Co Inc | HIV protease inhibitor compounds |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5538997A (en) * | 1993-03-12 | 1996-07-23 | Sandoz Ltd. | 2,4-diamino-3-hydroxycarboxylic acid derivatives |
AU6828894A (en) * | 1993-05-14 | 1994-12-12 | Merck & Co., Inc. | Hiv protease inhibitors |
EP0626178A1 (de) * | 1993-05-17 | 1994-11-30 | Ciba-Geigy Ag | Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen |
US5733882A (en) * | 1994-01-17 | 1998-03-31 | Smithkline Beecham Corporation | Retroviral protease inhibitors |
US5476874A (en) * | 1994-06-22 | 1995-12-19 | Merck & Co., Inc. | New HIV protease inhibitors |
ES2180600T3 (es) * | 1994-10-19 | 2003-02-16 | Novartis Ag | Eteres de isosteros substrato de aspartato proteasa antivirales. |
US5691368A (en) * | 1995-01-11 | 1997-11-25 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin B inhibitors |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
EP0906756A4 (en) * | 1996-04-04 | 2000-11-22 | Shionogi & Co | ANTI-HIV COMPOSITION CONTAINING IMIDAZOLE DERIVATIVE |
US5811462A (en) * | 1996-05-02 | 1998-09-22 | Merck & Co., Inc. | HIV Protease inhibitors useful for the treatment of AIDS |
US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US5962725A (en) | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
US5925759A (en) * | 1996-09-05 | 1999-07-20 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
AP1717A (en) | 1998-06-19 | 2007-01-30 | Vertex Pharma | Sulfonamide inhibitors of aspartyl protease. |
CA2336160C (en) | 1998-06-23 | 2015-02-17 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of compounds for treating hiv |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
US6384244B2 (en) | 2000-05-18 | 2002-05-07 | Merck & Co., Inc. | Process for preparing cis- aminochromanols |
US6531617B2 (en) | 2000-10-24 | 2003-03-11 | Merck & Co., Inc. | Process for preparing hydroxychomanones and cis-aminochromanols |
JP4741121B2 (ja) * | 2001-08-29 | 2011-08-03 | 株式会社吉谷機械製作所 | 作業車 |
DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
DE10207178A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Komponenten für die Herstellung amphoterer Liposomen |
CA2616314A1 (en) * | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
US11175724B2 (en) | 2017-03-01 | 2021-11-16 | Samsung Electronics Co., Ltd | Method and electronic device for enabling at least one battery management function for managing battery usage |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL89900A0 (en) * | 1988-04-12 | 1989-12-15 | Merck & Co Inc | Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them |
-
1990
- 1990-12-14 CA CA002032259A patent/CA2032259A1/en not_active Abandoned
- 1990-12-17 IE IE455590A patent/IE904555A1/en unknown
- 1990-12-17 NO NO90905428A patent/NO905428L/no unknown
- 1990-12-17 FI FI906212A patent/FI906212A/fi not_active Application Discontinuation
- 1990-12-17 HU HU908295A patent/HU908295D0/hu unknown
- 1990-12-17 IL IL9096691A patent/IL96691A0/xx unknown
- 1990-12-18 JP JP2419337A patent/JPH05345775A/ja not_active Withdrawn
- 1990-12-18 CN CN90110446A patent/CN1053607A/zh active Pending
- 1990-12-18 PT PT96234A patent/PT96234A/pt unknown
- 1990-12-18 KR KR1019900021105A patent/KR910011818A/ko not_active Application Discontinuation
- 1990-12-18 AU AU68229/90A patent/AU6822990A/en not_active Abandoned
- 1990-12-18 EP EP19900313848 patent/EP0434365A3/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IE904555A1 (en) | 1991-06-19 |
EP0434365A2 (en) | 1991-06-26 |
AU6822990A (en) | 1991-06-27 |
HU908295D0 (en) | 1991-06-28 |
EP0434365A3 (en) | 1991-11-27 |
FI906212A (fi) | 1991-06-19 |
PT96234A (pt) | 1991-10-15 |
JPH05345775A (ja) | 1993-12-27 |
NO905428D0 (no) | 1990-12-17 |
CA2032259A1 (en) | 1991-06-19 |
IL96691A0 (en) | 1991-09-16 |
NO905428L (no) | 1991-06-19 |
CN1053607A (zh) | 1991-08-07 |
FI906212A0 (fi) | 1990-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910011818A (ko) | Aids 치료에 유용한 hiv 프로테아제 억제제 | |
KR101799009B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
JP2003528072A (ja) | マトリックスメタロプロテアーゼおよびTNF−αの阻害剤としての環状β−アミノ酸誘導体 | |
JP3216136B2 (ja) | 抗不整脈ベンゾジアゼピン類 | |
KR930005985A (ko) | Hiv 역전사효소의 억제제 | |
US20060004073A1 (en) | Compounds, compositions, and methods | |
KR20060131908A (ko) | Cb1-길항 활성을 갖는 이미다졸린 유도체 | |
AU649812B2 (en) | New benzopyran compounds, process for preparing these and pharmaceutical compositions containing them | |
KR20010108518A (ko) | 카밤산 유도체 및 메타보트로픽 글루타메이트 수용체리간드로서의 그의 용도 | |
FR2885364A1 (fr) | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique | |
CN101300226B (zh) | 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法 | |
DE69635114T2 (de) | Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids | |
US5442055A (en) | Azetidinone compound and process for preparation thereof | |
KR950032185A (ko) | 신규한 단일환상 및 이중환상 dna 자이레이즈 저해제 | |
KR20040039495A (ko) | 신규 4-(2-푸로일)아미노피페리딘, 그의 합성 중간체,그의 제조방법 및 의약으로서의 그의 용도 | |
JPH05222020A (ja) | エイズの治療に有用なhivプロテアーゼインヒビター | |
KR950010894A (ko) | 자궁 섬유증의 억제 방법 | |
KR880006196A (ko) | 알레르기 및 염증 치료제인 디하이드로피리딘 | |
KR950703557A (ko) | 약제로서 사용되는 헤테로아릴 화합물(Heteroaryl Compounds Used as Pharmaceuticals) | |
EP3768661B1 (en) | Deuterated compounds as rock inhibitors | |
ZA200407709B (en) | Novel chalcone derivatives and uses thereof. | |
CA2132829C (en) | Novel derivatives of 2,3-dihydro-benzofuranols | |
KR20210108555A (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
EP0373590B1 (en) | Prodrugs of 3,4-hydroxy benzoyl-oxypropanolamines | |
EP0145956A1 (de) | Neue Amid-Verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |